Prolactin Receptor Expression and Breast Cancer: Relationships with Tumor Characteristics among Pre- and Post-menopausal Women in a Population-Based Case-Control Study from Poland

Hormones and Cancer

Volumn 5, Issue 1, 2014, Pages 42-50

  Faupel Badger, Jessica M ^a   Duggan, Maire A ^b   Sherman, Mark E ^a   Garcia Closas, Montserrat ^a,c   Yang, Xiaohong R ^a   Lissowska, Jolanta ^d   Brinton, Louise A ^a   Peplonska, Beata ^e   Vonderhaar, Barbara K ^a   Figueroa, Jonine D ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF CALGARY   (Canada)

^c INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^d INSTITUTE OF ONCOLOGY   (Poland)

^e NOFER INSTITUTE OF OCCUPATIONAL MEDICINE   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

PROLACTIN; PROLACTIN RECEPTOR;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER RISK; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MIDDLE AGED; POLAND; POSTMENOPAUSE; PREMENOPAUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RISK FACTOR; TISSUE MICROARRAY; YOUNG ADULT;

ADULT; AGED; BREAST NEOPLASMS; CARCINOGENESIS; CARCINOMA; CASE-CONTROL STUDIES; CELL DIFFERENTIATION; FEMALE; HUMANS; LOGISTIC MODELS; MENOPAUSE; MIDDLE AGED; POLAND; POPULATION GROUPS; PROGNOSIS; RECEPTORS, PROLACTIN; RISK FACTORS; TUMOR BURDEN; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84892482581     PISSN: 18688497     EISSN: 18688500     Source Type: Journal    
DOI: 10.1007/s12672-013-0165-7     Document Type: Article

References (36)

1. Binart N, Ormandy CJ, Kelly PA (2000) Mammary gland development and the prolactin receptor. Adv Exp Med Biol 480: 85-92.
2. Das R, Vonderhaar BK (1997) Prolactin as a mitogen in mammary cells. J Mammary Gland Biol Neoplasia 2: 29-39.
3. Hovey RC, Trott JF, Vonderhaar BK (2002) Establishing a framework for the functional mammary gland: from endocrinology to morphology. J Mammary Gland Biol Neoplasia 7: 17-38.
4. Ormandy CJ, Binart N, Kelly PA (1997) Mammary gland development in prolactin receptor knockout mice. J Mammary Gland Biol Neoplasia 2: 355-364.
5. Clevenger CV, Furth PA, Hankinson SE, Schuler LA (2003) The role of prolactin in mammary carcinoma. Endocr Rev 24: 1-27.
6. Maus MV, Reilly SC, Clevenger CV (1999) Prolactin as a chemoattractant for human breast carcinoma. Endocrinology 140: 5447-5450.
7. Vonderhaar BK (1999) Prolactin involvement in breast cancer. Endocr Relat Cancer 6: 389-404.
8. Faupel-Badger JM, Sherman ME, Garcia-Closas M, Gaudet MM, Falk RT, Andaya A, Pfeiffer RM, Yang XR, Lissowska J, Brinton LA et al (2010) Prolactin serum levels and breast cancer: relationships with risk factors and tumour characteristics among pre- and postmenopausal women in a population-based case-control study from Poland. Br J Cancer 103: 1097-1102.
9. Hankinson SE, Willett WC, Michaud DS, Manson JE, Colditz GA, Longcope C, Rosner B, Speizer FE (1999) Plasma prolactin levels and subsequent risk of breast cancer in postmenopausal women. J Natl Cancer Inst 91: 629-634.
10. Tworoger SS, Eliassen AH, Rosner B, Sluss P, Hankinson SE (2004) Plasma prolactin concentrations and risk of postmenopausal breast cancer. Cancer Res 64: 6814-6819.
11. Tworoger SS, Eliassen AH, Sluss P, Hankinson SE (2007) A prospective study of plasma prolactin concentrations and risk of premenopausal and postmenopausal breast cancer. J Clin Oncol 25: 1482-1488.
12. Tworoger SS, Sluss P, Hankinson SE (2006) Association between plasma prolactin concentrations and risk of breast cancer among predominately premenopausal women. Cancer Res 66: 2476-2482.
13. Tworoger SS, Eliassen AH, Zhang X, Qian J, Sluss PM, Rosner BA, Hankinson SE (2013) A 20-year prospective study of plasma prolactin as a risk marker of breast cancer development. Cancer Res 73: 4810-4819.
14. Gill S, Peston D, Vonderhaar BK, Shousha S (2001) Expression of prolactin receptors in normal, benign, and malignant breast tissue: an immunohistological study. J Clin Pathol 54: 956-960.
15. Reynolds C, Montone KT, Powell CM, Tomaszewski JE, Clevenger CV (1997) Expression of prolactin and its receptor in human breast carcinoma. Endocrinology 138: 5555-5560.
16. Touraine P, Martini JF, Zafrani B, Durand JC, Labaille F, Malet C, Nicolas A, Trivin C, Postel-Vinay MC, Kuttenn F et al (1998) Increased expression of prolactin receptor gene assessed by quantitative polymerase chain reaction in human breast tumors versus normal breast tissues. J Clin Endocrinol Metab 83: 667-674.
17. Trott JF, Hovey RC, Koduri S, Vonderhaar BK (2003) Alternative splicing to exon 11 of human prolactin receptor gene results in multiple isoforms including a secreted prolactin-binding protein. J Mol Endocrinol 30: 31-47.
18. Glasow A, Haidan A, Gillespie J, Kelly PA, Chrousos GP, Bornstein SR (1998) Differential expression of prolactin receptor (PRLR) in normal and tumorous adrenal tissues: separation of cellular endocrine compartments by laser capture microdissection (LCM). Endocr Res 24: 857-862.
19. Mertani HC, Garcia-Caballero T, Lambert A, Gerard F, Palayer C, Boutin JM, Vonderhaar BK, Waters MJ, Lobie PE, Morel G (1998) Cellular expression of growth hormone and prolactin receptors in human breast disorders. Int J Cancer 79: 202-211.
20. Garcia-Closas M, Brinton LA, Lissowska J, Chatterjee N, Peplonska B, Anderson WF, Szeszenia-Dabrowska N, Bardin-Mikolajczak A, Zatonski W, Blair A et al (2006) Established breast cancer risk factors by clinically important tumour characteristics. Br J Cancer 95: 123-129.
21. Yang XR, Pfeiffer RM, Garcia-Closas M, Rimm DL, Lissowska J, Brinton LA, Peplonska B, Hewitt SM, Cartun RW, Mandich D et al (2007) Hormonal markers in breast cancer: coexpression, relationship with pathologic characteristics, and risk factor associations in a population-based study. Cancer Res 67: 10608-10617.
22. Yang XR, Sherman ME, Rimm DL, Lissowska J, Brinton LA, Peplonska B, Hewitt SM, Anderson WF, Szeszenia-Dabrowska N, Bardin-Mikolajczak A et al (2007) Differences in risk factors for breast cancer molecular subtypes in a population-based study. Cancer Epidemiol Biomarkers Prev 16: 439-443.
23. Sherman ME, Rimm DL, Yang XR, Chatterjee N, Brinton LA, Lissowska J, Peplonska B, Szeszenia-Dabrowska N, Zatonski W, Cartun R et al (2007) Variation in breast cancer hormone receptor and HER2 levels by etiologic factors: a population-based analysis. Int J Cancer 121: 1079-1085.
24. Galsgaard ED, Rasmussen BB, Folkesson CG, Rasmussen LM, Berchtold MW, Christensen L, Panina S (2009) Re-evaluation of the prolactin receptor expression in human breast cancer. J Endocrinol 201: 115-128.
25. Sato T, Tran TH, Peck AR, Liu C, Ertel A, Lin J, Neilson LM, Rui H (2013) Global profiling of prolactin-modulated transcripts in breast cancer in vivo. Mol Cancer 12: 59.
26. Cotarla I, Ren S, Zhang Y, Gehan E, Singh B, Furth PA (2004) Stat5a is tyrosine phosphorylated and nuclear localized in a high proportion of human breast cancers. Int J Cancer 108: 665-671.
27. Nevalainen MT, Xie J, Torhorst J, Bubendorf L, Haas P, Kononen J, Sauter G, Rui H (2004) Signal transducer and activator of transcription-5 activation and breast cancer prognosis. J Clin Oncol 22: 2053-2060.
28. Peck AR, Witkiewicz AK, Liu C, Klimowicz AC, Stringer GA, Pequignot E, Freydin B, Yang N, Ertel A, Tran TH et al (2012) Low levels of Stat5a protein in breast cancer are associated with tumor progression and unfavorable clinical outcomes. Breast Cancer Res: BCR 14: R130.
29. Peck AR, Witkiewicz AK, Liu C, Stringer GA, Klimowicz AC, Pequignot E, Freydin B, Tran TH, Yang N, Rosenberg AL et al (2011) Loss of nuclear localized and tyrosine phosphorylated Stat5 in breast cancer predicts poor clinical outcome and increased risk of antiestrogen therapy failure. J Clin Oncol 29: 2448-2458.
30. Yamashita H, Nishio M, Ando Y, Zhang Z, Hamaguchi M, Mita K, Kobayashi S, Fujii Y, Iwase H (2006) Stat5 expression predicts response to endocrine therapy and improves survival in estrogen receptor-positive breast cancer. Endocr Relat Cancer 13: 885-893.
31. Camp RL, Charette LA, Rimm DL (2000) Validation of tissue microarray technology in breast carcinoma. Lab Invest 80: 1943-1949.
32. Hu ZZ, Meng J, Dufau ML (2001) Isolation and characterization of two novel forms of the human prolactin receptor generated by alternative splicing of a newly identified exon 11. J Biol Chem 276: 41086-41094.
33. Kline JB, Roehrs H, Clevenger CV (1999) Functional characterization of the intermediate isoform of the human prolactin receptor. J Biol Chem 274: 35461-35468.
34. Kline JB, Rycyzyn MA, Clevenger CV (2002) Characterization of a novel and functional human prolactin receptor isoform (deltaS1PRLr) containing only one extracellular fibronectin-like domain. Mol Endocrinol 16: 2310-2322.
35. Trott JF, Hovey RC, Koduri S, Vonderhaar BK (2004) Multiple new isoforms of the human prolactin receptor gene. Adv Exp Med Biol 554: 495-499.
36. Nitze LM, Galsgaard ED, Din N, Lund VL, Rasmussen BB, Berchtold MW, Christensen L, Panina S (2013) Reevaluation of the proposed autocrine proliferative function of prolactin in breast cancer. Breast Cancer Res Treat. DOI 10. 1007/s10549-013-2731-7. In press.